Integrated Nanovaccine with MicroRNA-148a Inhibition Reprograms Tumor-Associated Dendritic Cells by Modulating miR-148a/DNMT1/SOCS1 Axis
39
Citation
54
Reference
10
Related Paper
Citation Trend
Abstract:
Immunosuppressive tumor-associated dendritic cells (TADCs) are potential targets for cancer therapy. However, their poor responsiveness to TLR stimulation is a major obstacle for achieving successful cancer immunotherapy. In the current study, we reported a dysregulated miR-148a/DNA methyltransferase (DNMT)1/suppressor of cytokine signaling (SOCS)1 axis as a unique mechanism for dampened TLR stimulation in TADCs. The results showed that aberrantly elevated miR-148a in bone marrow-derived TADC (BM-TADC) abolished polyinosinic-polycytidylic acid (poly I:C) or LPS-induced dendritic cell maturation through directly suppressing DNMT1 gene, which consequently led to the hypomethylation and upregulation of SOCS1, the suppressor of TLR signaling. In contrast, miR-148a inhibitor (miR-148ai) effectively rescued the expression of DNMT1 and decreased SOCS1 in BM-TADCs, thereby recovering their sensitivity to TLR3 or TLR4 stimulation. To further reprogram TADCs in vivo, miR-148ai was coencapsulated with poly I:C and OVA by cationic polypeptide micelles to generate integrated polypeptide micelle/poly I:C (PMP)/OVA/148ai nanovaccine, which was designed to simultaneously inhibit miR-148a and activate TLR3 signaling in TADCs. The immunization of PMP/OVA/148ai nanovaccine not only effectively modulated the miR-148a/DNMT1/SOCS1 axis in the spleen, but also significantly increased mature dendritic cells both in the spleen and in tumor microenvironment. Moreover, PMP/OVA/148ai ameliorated tumor immunosuppression through reducing regulatory T cells and myeloid-derived suppressor cells, thereby leading to potent anticancer immune responses and robust tumor regression with prolonged survival. This study proposes a nanovaccine-based immunogene therapy with the integration of miR-148a inhibition and TLR3 stimulation as a novel therapeutic approach to boost anticancer immunity by reprogramming TADCs in vivo.Keywords:
DNMT1
DNMT1
Cite
Citations (1)
Cite
Citations (22)
Abstract Dysregulated leukocyte activation and cytokine signaling are known to contribute to autoimmunity. Notably, although Suppressor of Cytokine Signaling-1(SOCS1) is important in the regulation of both leukocyte activation and cytokine signaling, how deficiencies in SOCS1 relate to autoimmunity is not well understood. Therefore we analyzed leukocytes from mice bearing heterozygous expression of SOCS1 (SOCS1+/-) for dysregulated immune function. LPS stimulated SOCS1+/- leukocytes exhibited enhanced production of IL6, and IL12. Notably we observed that SOCS1+/-IFNγ-/- mice, but not IFNγ-/-, SOCS1+/-, or wild-type mice exhibited significant skin pathology on the back and ears. The observed skin pathology in SOCS1-/-IFNγ-/- mice was correlated to leukocyte accumulation within draining lymph nodes and spleen. In vitro, SOCS1+/-IFNγ-/- leukocytes activated with αCD3/αCD28 were hyper-proliferative and produced higher levels of IL17 when compared SOCS1+/+ littermates. Finally, a peptide capable of partially mimicking SOCS1 (SOCS1-KIR) was sufficient to reduce excessive proliferation, and aberrant IL12 and IL6 production of SOCS1+/- leukocytes in vitro. Together these results implicate an important role of SOCS1 in the regulation of immune responses. Moreover these results suggest that targeting SOCS1 deficiency, by a mimetic of SOCS1, may have implications in the regulation of skin pathologies mediated by immune dysregulation.
Cite
Citations (0)
Cite
Citations (17)
Maternal viral infection is known to increase the risk for schizophrenia and autism in their offspring (Brown et al, 2004). C57BL/6 mice were infected with human influenza virus on day E18 of pregnancy and brains were collected at PN days 0, 14, or 56, from virally-exposed (N=3) or sham-infected control's (N=3) offspring. Microarray analysis of virally-exposed mouse brains showed significant (p<0.05) upregulation of 15 genes and downregulation of 3 genes in cerebellum, upregulation of 42 genes and downregulation of 9 genes in hippocampus, and upregulation of 4 genes and downregulation of 5 genes in prefrontal cortex vs. controls in day 0 mice. At day 14, there was a significant upregulation of 2 genes and downregulation of 0 genes in cerebellum, upregulation of 1 gene and downregulation of 1 gene in hippocampus, and upregulation of 3 genes and downregulation of 3 genes in prefrontal cortex vs. controls. At day 56, there was a significant upregulation of 13 genes and downregulation of 2 genes in cerebellum, upregulation of 4 genes and downregulation of 3 genes in hippocampus, and upregulation of 4 genes and downregulation of 1 gene in prefrontal cortex vs. controls. Implications of changes in brain genes for development of abnormal brain structure and function will be discussed. The generous support by the National Institute for Child Health and Human Development (1-R01-HD046589-01A2) to S.H.F. is greatly appreciated.
Cite
Citations (1)
Cancer cells differ from normal cells in both gain of functions (i.e., upregulation) and loss of functions (i.e., downregulation). While it is common to suppress gain of function for chemotherapy, it remains challenging to target downregulation in cancer cells. Here we show the combination of enzyme-instructed assembly and disassembly to target downregulation in cancer cells by designing peptidic precursors as the substrates of both carboxylesterases (CESs) and alkaline phosphatases (ALPs). The precursors turn into self-assembling molecules to form nanofibrils upon dephosphorylation by ALP, but CES-catalyzed cleavage of the ester bond on the molecules results in disassembly of the nanofibrils. The precursors selectively inhibit the cancer cells that downregulate CES (e.g., OVSAHO) but are innocuous to a hepatocyte that overexpresses CES (HepG2), while the two cell lines exhibit comparable ALP activities. This work illustrates a potential approach for the development of chemotherapy via targeting downregulation (or loss of functions) in cancer cells.
Dephosphorylation
Cite
Citations (135)
SKP2
Cite
Citations (8)
SOCS2
SOCS6
SOCS5
Cite
Citations (23)
Suppressor of cytokine signaling-1 (SOCS1) is a negative feedback regulator of cytokine signaling,such as interferon,interleukin-4.SOCS1 is regulated on transcription,translation and protein level.Appropriate SOCS1 expression can attenuate the inflammation in asthma,while inappropriate SOCS1 expression may increase the morbidity of asthma.SOCS1 can prevent lethal inflammation in lung infection,while it can also compromise pathogen eradication.SOCS1 mediates the interleukin-6 cyto-protection in hyperoxic acute lung injury.Idiopathic lung fibrosis and aberrant collagen production may be linked to diminished SOCS1 expression,and SOCS1 can suppress the lung fibrosis induced by bleomycin.In conclusion,SOCS1 plays an important role in many lung diseases,but the panorama and significance of SOCS1 regulation still remain to be elucidated.
Key words:
Suppressor of cytokine signaling- 1 ; Signal transduction; Lung diseases
Cite
Citations (0)
Abstract Suppressor of cytokine signalling‐1 (SOCS1), as the name implies, is a protein that functions as a negative regulator of cytokine signalling. Initially characterized for its ability to inhibit JAK phosphorylation and function, SOCS1 also targets proteins for degradation by the proteosome machinery. The expression of SOCS1 can be regulated at the transcription, translation and protein level. Despite the broad spectrum of cytokines that can induce SOCS1 expression and/or be inhibited by SOCS1 in vitro , the use of genetically modified mice has revealed a more specific role for SOCS1 in vivo including a critical role in the regulation of IFNγ signalling. In addition, SOCS1 has a complex role in T cell activation, and studies have revealed significant roles for SOCS1 in the regulation of IL‐4, IL‐12 and IL‐15 in vivo . Interestingly, SOCS1 action is not limited to the regulation of the classical JAK/STAT‐signalling pathway, because SOCS1 also inhibits cytokines like insulin and toll‐like receptor signal transduction, neither of which activates the JAK/STAT pathway. Evidence is emerging for a role for aberrant SOCS1 expression in human disease, particularly in a number of malignancies.
Cite
Citations (114)